NASDAQ: $KOD
Kodiak Sciences Inc. has announced significant progress in its clinical and scientific programs, with plans to present new data at the 2026 American Uveitis Society (AUS) Meeting and the Association for Research in Vision and Ophthalmology (ARVO) Meeting. These updates center on the clinical performance of KSI-101 in treating macular edema secondary to inflammation (MESI) and the broader expansion of the company’s multi-modal therapeutic platforms.
Validation of KSI-101 in Global Clinical Cohorts
A major focus of the upcoming presentations is the consistency of KSI-101 across diverse patient populations. Recent data from a tertiary care uveitis practice in Asia show that outcomes for patients treated with KSI-101 mirror those seen in the U.S. Phase 1b APEX study. In the Asian cohort, patients achieved meaningful visual improvements, including a 58% rate of ?15-letter gains and a mean best-corrected visual acuity (BCVA) increase of +17.8 letters at Week 24. Furthermore, central subfield thickness was significantly reduced after a single injection, with sustained retinal dryness during the follow-up period.
Dr. Pablo Velazquez-Martin, Chief Medical Officer at Kodiak, noted that these results bolster the evidence for KSI-101 as a potential treatment for MESI, regardless of the underlying disease severity or etiology. The success of these trials supports the ongoing Phase 3 PEAK and PINNACLE studies, which are actively recruiting.
Addressing Ocular Inflammatory Disease and Geographic Atrophy
Kodiak is also addressing the limitations of current, single-target therapies for ocular inflammation and geographic atrophy (GA). Given that ocular inflammatory disease is the fourth leading cause of vision loss among working-age adults—and that current standard-of-care steroids carry significant risks—Kodiak is developing bispecific biologics such as KSI-102 and KSI-103. These molecules are designed to inhibit multiple cytokines, such as TNF-? and IL-6, simultaneously, providing a more comprehensive approach to managing retinal inflammation.
For patients with geographic atrophy, Kodiak is investigating a “duet” strategy. By fusing complement inhibitors with anti-VEGF or anti-IL-6, the company aims to move beyond the modest benefits of existing anti-complement therapies, which often require frequent injections and may carry risks of choroidal neovascularization.
The ABCD Platform™: A New Frontier in Drug Delivery
The company continues to evolve its proprietary ABCD platform, moving toward the integration of small molecules to create high drug-antibody ratio (DAR) therapeutics. Recent mechanistic studies demonstrate that antibody-biopolymer conjugates (ABCs) can effectively internalize into cells and persist, facilitating targeted delivery. This versatility is further illustrated by a new glaucoma candidate that utilizes the ABCD platform to deliver two distinct small molecules—an NLRP3 inflammasome inhibitor for neuroprotection and an IOP-lowering agent—simultaneously. This development highlights the potential for the platform to address the multifactorial nature of optic neuropathies.
Upcoming Presentations
Kodiak will detail these findings in several key presentations:
- American Uveitis Society (May 2, 2026): Dr. Edmund Tsui will present Week 24 results from the Phase 1b APEX study.
- ARVO (May 3–7, 2026): Kodiak will deliver six poster presentations covering the Asian MESI clinical cohort, translational uveitis research, and preclinical advancements in GA and glaucoma treatment.
The company remains committed to building a portfolio of transformative retina-focused therapeutics, utilizing its scientific pipeline to create more durable and effective solutions for patients worldwide.